✦ LIBER ✦

Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors

✍ Scribed by Adam M. Brufsky

Book ID: 107546570
Publisher: Current Science Inc.
Year: 2008
Tongue: English
Weight: 270 KB
Volume: 10
Category: Article
ISSN: 1523-3790
DOI: 10.1007/s11912-008-0005-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Summary of aromatase inhibitor clinical

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

✍ Aman U. Buzdar; R. Charles Coombes; Paul E. Goss; Eric P. Winer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge

Aromatase Inhibitors in the Adjuvant Tre

Aromatase Inhibitors in the Adjuvant Treatment of Postmenopausal Women with Early Breast Cancer: Putting Safety Issues into Perspective

✍ PierFranco Conte; Antonio Frassoldati 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

Prospective characterization of musculos

Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

✍ N. Lynn Henry; Jon T. Giles; Dennis Ang; Monika Mohan; Dina Dadabhoy; Jason Roba 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 208 KB

Use of aromatase inhibitors in postmenop

Use of aromatase inhibitors in postmenopausal women with advanced breast cancer

✍ Roseman, Barry J.; Buzdar, Aman U.; Singletary, S. Eva 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB 👁 2 views

Surgeons have been involved in the management of metastatic breast cancer since the technique of ovarian ablation was introduced in 1896. However, as newer hormonal and chemotherapeutic regimens were developed, drug therapy gradually replaced surgery as the preferred treatment for metastatic breast

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

Optimizing aromatase inhibitor integrati

Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer

✍ Rowan T. Chlebowski 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 274 KB